251 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
2 Stocks That Could Benefit Big From Geron's Stumble https://www.fool.com/investing/2018/09/29/2-stocks-that-could-benefit-big-from-gerons-stumbl.aspx?source=iedfolrf0000001 Sep 29, 2018 - A disappointing decision could mean one fewer competitor for these biotech companies.
Merck Gets Priority Review for Yet Another Keytruda sBLA http://www.zacks.com/stock/news/322981/merck-gets-priority-review-for-yet-another-keytruda-sbla?cid=CS-ZC-FT-322981 Sep 13, 2018 - Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars http://www.zacks.com/stock/news/322780/biotech-stock-roundup-gilds-arthritis-drug-successful-in-phase-iii-prqr-soars?cid=CS-ZC-FT-322780 Sep 12, 2018 - Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Incyte, Foundation Medicine Partner for Companion Diagnostics http://www.zacks.com/stock/news/322760/incyte-foundation-medicine-partner-for-companion-diagnostics?cid=CS-ZC-FT-322760 Sep 12, 2018 - Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe http://www.zacks.com/stock/news/322513/mercks-keytruda-combo-gets-nod-for-lung-cancer-in-europe?cid=CS-ZC-FT-322513 Sep 11, 2018 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
Merck's Keytruda Gets Priority Review for Rare Skin Cancer http://www.zacks.com/stock/news/321571/mercks-keytruda-gets-priority-review-for-rare-skin-cancer?cid=CS-ZC-FT-321571 Sep 05, 2018 - Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat http://www.zacks.com/stock/news/317485/agenus-agen-q2-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-317485 Aug 10, 2018 - Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
The 3 Worst Healthcare Stocks of 2018 (So Far) https://www.fool.com/investing/2018/07/19/the-3-worst-healthcare-stocks-of-2018-so-far.aspx?source=iedfolrf0000001 Jul 19, 2018 - Find out how three companies have lost their shareholders a combined $31 billion so far this year.
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA http://www.zacks.com/stock/news/312300/cti-biopharma-tanks-post-type-b-talks-on-pacritinib-with-fda?cid=CS-ZC-FT-312300 Jul 19, 2018 - CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2? http://www.zacks.com/stock/news/312213/can-eli-lilly-lly-keep-the-earnings-streak-alive-in-q2?cid=CS-ZC-FT-312213 Jul 19, 2018 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

Pages: 123456789101112...26

<<<Page 7>